Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2007-2012

ABSTRACT

This study will try to improve the safety and effectiveness of stem cell transplant procedures in patients with cancers of the blood. It will use a special machine to separate immune cells (T cells) from the blood of both the donor and the patient and will use photodepletion, a laboratory procedure that selectively kills cancer cells exposed to light. These special procedures may reduce the risk of graft-versus-host-disease (GVHD), a serious complication of stem cell transplants in which the donor's immune cells destroy the patient's healthy tissues, and at the same time may permit a greater graft-versus-leukemia effect, in which the donated cells fight any residual tumor cells that might remain in the body. Patients between 18 and 75 years of age with a life-threatening disease of the bone marrow (acute or chronic leukemia, myelodysplastic syndrome, or myeloproliferative syndrome) may be eligible for this study. Candidates must have a family member who is a suitable tissue match. Detailed Description Peripheral blood stem cell transplant research carried out by the NHLBI BMT Unit focus on approaches in transplant techniques designed to decrease graft versus host disease (GVHD), increase the graft-versus-leukemia (GVL) effect, and/or reduce the risk for post-transplant graft rejection or disease relapse. Ex vivo selective depletion of alloreacting T cells, hereafter referred as selective depletion (SD), represents a translational strategy aiming to reduce severe GVHD whilst preserving GVL. We found that selectively depleted transplants are safe to administer and associated with less severe acute GVHD. This protocol is designed to evaluate the safety and efficacy of photodepletion (PD) as an improved selective depletion procedure in the HLA-matched peripheral blood stem cell transplant setting and to determine whether post-transplant immunosuppression with cyclosporine is necessary to prevent severe GVHD after a photodepleted transplant. The protocol will accrue subjects ages 18-75 who are diagnosed with a hematological malignancy where allogeneic stem cell transplantation from an HLA-matched sibling would be normally indicated. Diagnostic categories will include acute and chronic leukemias, myelodysplastic syndromes, B-cell lymphomas, multiple myeloma, and myeloproliferative syndromes. Participants have a central intravenous (IV) line placed into a large vein. The tube is used for giving the donated stem cells and antibiotics and other medicines, for transfusions of red blood cells and platelets, and for collecting blood samples. Treatment starts with a conditioning regimen of chemotherapy (fludarabine and cyclophosphamide) and total body irradiation to suppress immunity and prevent rejection of the donated stem cells. The day after chemotherapy ends, the stem cells are given through the central line. This is followed by transfusion of the donor's immune cells, which have been treated to remove cells that could cause severe GVHD. Also to minimize the risk of GVHD, patients are given cyclosporine. Not all participants receive the same amount of this drug; in order to determine how much immunosuppression is needed to protect against severe GVHD, the length of treatment with cyclosporine varies among patients, depending on when they entered the study and how well preceding patients did. The average hospital stay for stem cell transplantation is 3 to 4 weeks. Patients return for frequent follow-up visits for the first 2 to 4 months after transplantation. The patient's referring physician is asked to send results of any laboratory testing to the NIH researchers at least every 3 months for the first 3 years and annually thereafter. Patient follow-up visits are scheduled at NIH at 1, 2, and 3 years after transplantation. After 3 years, participants are offered the opportunity to enroll in NHLBI's long-term evaluation and follow-up care protocol. Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach (Kiadis Pharma). Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, we will utilize a three sequential de-escalation stage design involving 17 subjects per cohort (minimum 17, maximum 51 total evaluable subjects in study). Stopping rules for non-relapse mortality in each cohort will determine whether to continue to the next stage; to continue accumulating subjects at the same level; or to stop the protocol. Cohort 1: Low dose cyclosporine until day 90 then dose tapered to stop within 2 weeks. Cohort 2: If no severe GVHD is encountered in Cohort 1, the cyclosporine withdrawal will begin on day 45. Cohort 3: If no severe GVHD is encountered in Cohort 2, cyclosporine will not be used in the post-transplant period. Primary endpoints will be the incidence of acute grade III/IV GVHD at day 90. Secondary endpoints will be standard transplant outcome variables: toxicity, non relapse mortality and survival. More... »

URL

https://clinicaltrials.gov/show/NCT00467961

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study will try to improve the safety and effectiveness of stem cell transplant procedures in patients with cancers of the blood. It will use a special machine to separate immune cells (T cells) from the blood of both the donor and the patient and will use photodepletion, a laboratory procedure that selectively kills cancer cells exposed to light. These special procedures may reduce the risk of graft-versus-host-disease (GVHD), a serious complication of stem cell transplants in which the donor's immune cells destroy the patient's healthy tissues, and at the same time may permit a greater graft-versus-leukemia effect, in which the donated cells fight any residual tumor cells that might remain in the body. Patients between 18 and 75 years of age with a life-threatening disease of the bone marrow (acute or chronic leukemia, myelodysplastic syndrome, or myeloproliferative syndrome) may be eligible for this study. Candidates must have a family member who is a suitable tissue match.\n\nDetailed Description\nPeripheral blood stem cell transplant research carried out by the NHLBI BMT Unit focus on approaches in transplant techniques designed to decrease graft versus host disease (GVHD), increase the graft-versus-leukemia (GVL) effect, and/or reduce the risk for post-transplant graft rejection or disease relapse. Ex vivo selective depletion of alloreacting T cells, hereafter referred as selective depletion (SD), represents a translational strategy aiming to reduce severe GVHD whilst preserving GVL. We found that selectively depleted transplants are safe to administer and associated with less severe acute GVHD. This protocol is designed to evaluate the safety and efficacy of photodepletion (PD) as an improved selective depletion procedure in the HLA-matched peripheral blood stem cell transplant setting and to determine whether post-transplant immunosuppression with cyclosporine is necessary to prevent severe GVHD after a photodepleted transplant. The protocol will accrue subjects ages 18-75 who are diagnosed with a hematological malignancy where allogeneic stem cell transplantation from an HLA-matched sibling would be normally indicated. Diagnostic categories will include acute and chronic leukemias, myelodysplastic syndromes, B-cell lymphomas, multiple myeloma, and myeloproliferative syndromes. Participants have a central intravenous (IV) line placed into a large vein. The tube is used for giving the donated stem cells and antibiotics and other medicines, for transfusions of red blood cells and platelets, and for collecting blood samples. Treatment starts with a conditioning regimen of chemotherapy (fludarabine and cyclophosphamide) and total body irradiation to suppress immunity and prevent rejection of the donated stem cells. The day after chemotherapy ends, the stem cells are given through the central line. This is followed by transfusion of the donor's immune cells, which have been treated to remove cells that could cause severe GVHD. Also to minimize the risk of GVHD, patients are given cyclosporine. Not all participants receive the same amount of this drug; in order to determine how much immunosuppression is needed to protect against severe GVHD, the length of treatment with cyclosporine varies among patients, depending on when they entered the study and how well preceding patients did. The average hospital stay for stem cell transplantation is 3 to 4 weeks. Patients return for frequent follow-up visits for the first 2 to 4 months after transplantation. The patient's referring physician is asked to send results of any laboratory testing to the NIH researchers at least every 3 months for the first 3 years and annually thereafter. Patient follow-up visits are scheduled at NIH at 1, 2, and 3 years after transplantation. After 3 years, participants are offered the opportunity to enroll in NHLBI's long-term evaluation and follow-up care protocol. Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach (Kiadis Pharma). Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, we will utilize a three sequential de-escalation stage design involving 17 subjects per cohort (minimum 17, maximum 51 total evaluable subjects in study). Stopping rules for non-relapse mortality in each cohort will determine whether to continue to the next stage; to continue accumulating subjects at the same level; or to stop the protocol. Cohort 1: Low dose cyclosporine until day 90 then dose tapered to stop within 2 weeks. Cohort 2: If no severe GVHD is encountered in Cohort 1, the cyclosporine withdrawal will begin on day 45. Cohort 3: If no severe GVHD is encountered in Cohort 2, cyclosporine will not be used in the post-transplant period. Primary endpoints will be the incidence of acute grade III/IV GVHD at day 90. Secondary endpoints will be standard transplant outcome variables: toxicity, non relapse mortality and survival.", 
    "endDate": "2012-11-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00467961", 
    "keywords": [
      "selective depletion", 
      "T cell", 
      "technique", 
      "Prevent", 
      "peripheral blood stem cell", 
      "Hematologic Neoplasm", 
      "safety", 
      "effectiveness", 
      "stem cell transplant", 
      "patient", 
      "Neoplasm", 
      "blood", 
      "machine", 
      "immune cell", 
      "Tissue Donor", 
      "laboratory procedure", 
      "cancer cell", 
      "light", 
      "risk", 
      "graft-versus-host-disease", 
      "serious complication", 
      "healthy tissue", 
      "same time", 
      "graft-versus-leukemia effect", 
      "cell", 
      "residual tumor cell", 
      "body", 
      "age", 
      "life-threatening disease", 
      "bone marrow", 
      "chronic leukemia", 
      "myelodysplastic syndrome", 
      "syndrome", 
      "family", 
      "tissue", 
      "unit", 
      "Transplant", 
      "graft host disease", 
      "Graft vs Host Disease", 
      "graft-versus-leukemia", 
      "post-transplant", 
      "disease relapse", 
      "translational strategy", 
      "administer", 
      "acute graft versus host disease", 
      "protocol", 
      "efficacy", 
      "PD", 
      "Cyclosporine", 
      "host disease", 
      "accrue", 
      "allogeneic stem cell transplantation", 
      "sibling", 
      "diagnostic category", 
      "B-cell lymphoma", 
      "multiple myeloma", 
      "vein", 
      "tube", 
      "stem cell", 
      "antibiotic", 
      "medicine", 
      "transfusion", 
      "Erythrocyte", 
      "Blood Platelet", 
      "blood sample", 
      "conditioning regimen", 
      "Drug Therapy", 
      "fludarabine", 
      "cyclophosphamide", 
      "Whole-Body Irradiation", 
      "immunity", 
      "rejection", 
      "same amount", 
      "drug", 
      "Immune Tolerance", 
      "hospital", 
      "stem cell transplantation", 
      "follow-up visit", 
      "transplantation", 
      "physician", 
      "laboratory testing", 
      "NIH researcher", 
      "NIH", 
      "NHLBI's", 
      "long-term evaluation", 
      "follow-up care", 
      "infusion", 
      "cell product", 
      "selection", 
      "lymphocyte", 
      "pharma", 
      "low dose", 
      "irradiation", 
      "intensity", 
      "appropriate level", 
      "de-escalation", 
      "cohort", 
      "maximum", 
      "rule", 
      "mortality", 
      "stage", 
      "same level", 
      "stop", 
      "cohort 1", 
      "dose", 
      "cohort 2", 
      "primary endpoint", 
      "incidence", 
      "grade", 
      "secondary endpoint", 
      "transplant outcome", 
      "toxicity", 
      "survival"
    ], 
    "name": "Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00467961"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00003.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.279885.9", 
        "type": "Organization"
      }
    ], 
    "startDate": "2007-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/bmt.2013.39", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008987049", 
          "https://doi.org/10.1038/bmt.2013.39"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbmt.2011.05.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013988099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35077251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023027862", 
          "https://doi.org/10.1038/35077251"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2011.053363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032739336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-11-3516", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036792469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)09413-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044804794"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00467961"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00467961'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00467961'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00467961'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00467961'


 

This table displays all metadata directly associated to this object as RDF triples.

157 TRIPLES      16 PREDICATES      136 URIs      122 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00467961 schema:about anzsrc-for:3048
2 anzsrc-for:3103
3 schema:description This study will try to improve the safety and effectiveness of stem cell transplant procedures in patients with cancers of the blood. It will use a special machine to separate immune cells (T cells) from the blood of both the donor and the patient and will use photodepletion, a laboratory procedure that selectively kills cancer cells exposed to light. These special procedures may reduce the risk of graft-versus-host-disease (GVHD), a serious complication of stem cell transplants in which the donor's immune cells destroy the patient's healthy tissues, and at the same time may permit a greater graft-versus-leukemia effect, in which the donated cells fight any residual tumor cells that might remain in the body. Patients between 18 and 75 years of age with a life-threatening disease of the bone marrow (acute or chronic leukemia, myelodysplastic syndrome, or myeloproliferative syndrome) may be eligible for this study. Candidates must have a family member who is a suitable tissue match. Detailed Description Peripheral blood stem cell transplant research carried out by the NHLBI BMT Unit focus on approaches in transplant techniques designed to decrease graft versus host disease (GVHD), increase the graft-versus-leukemia (GVL) effect, and/or reduce the risk for post-transplant graft rejection or disease relapse. Ex vivo selective depletion of alloreacting T cells, hereafter referred as selective depletion (SD), represents a translational strategy aiming to reduce severe GVHD whilst preserving GVL. We found that selectively depleted transplants are safe to administer and associated with less severe acute GVHD. This protocol is designed to evaluate the safety and efficacy of photodepletion (PD) as an improved selective depletion procedure in the HLA-matched peripheral blood stem cell transplant setting and to determine whether post-transplant immunosuppression with cyclosporine is necessary to prevent severe GVHD after a photodepleted transplant. The protocol will accrue subjects ages 18-75 who are diagnosed with a hematological malignancy where allogeneic stem cell transplantation from an HLA-matched sibling would be normally indicated. Diagnostic categories will include acute and chronic leukemias, myelodysplastic syndromes, B-cell lymphomas, multiple myeloma, and myeloproliferative syndromes. Participants have a central intravenous (IV) line placed into a large vein. The tube is used for giving the donated stem cells and antibiotics and other medicines, for transfusions of red blood cells and platelets, and for collecting blood samples. Treatment starts with a conditioning regimen of chemotherapy (fludarabine and cyclophosphamide) and total body irradiation to suppress immunity and prevent rejection of the donated stem cells. The day after chemotherapy ends, the stem cells are given through the central line. This is followed by transfusion of the donor's immune cells, which have been treated to remove cells that could cause severe GVHD. Also to minimize the risk of GVHD, patients are given cyclosporine. Not all participants receive the same amount of this drug; in order to determine how much immunosuppression is needed to protect against severe GVHD, the length of treatment with cyclosporine varies among patients, depending on when they entered the study and how well preceding patients did. The average hospital stay for stem cell transplantation is 3 to 4 weeks. Patients return for frequent follow-up visits for the first 2 to 4 months after transplantation. The patient's referring physician is asked to send results of any laboratory testing to the NIH researchers at least every 3 months for the first 3 years and annually thereafter. Patient follow-up visits are scheduled at NIH at 1, 2, and 3 years after transplantation. After 3 years, participants are offered the opportunity to enroll in NHLBI's long-term evaluation and follow-up care protocol. Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach (Kiadis Pharma). Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, we will utilize a three sequential de-escalation stage design involving 17 subjects per cohort (minimum 17, maximum 51 total evaluable subjects in study). Stopping rules for non-relapse mortality in each cohort will determine whether to continue to the next stage; to continue accumulating subjects at the same level; or to stop the protocol. Cohort 1: Low dose cyclosporine until day 90 then dose tapered to stop within 2 weeks. Cohort 2: If no severe GVHD is encountered in Cohort 1, the cyclosporine withdrawal will begin on day 45. Cohort 3: If no severe GVHD is encountered in Cohort 2, cyclosporine will not be used in the post-transplant period. Primary endpoints will be the incidence of acute grade III/IV GVHD at day 90. Secondary endpoints will be standard transplant outcome variables: toxicity, non relapse mortality and survival.
4 schema:endDate 2012-11-01T00:00:00Z
5 schema:keywords B-cell lymphoma
6 Blood Platelet
7 Cyclosporine
8 Drug Therapy
9 Erythrocyte
10 Graft vs Host Disease
11 Hematologic Neoplasm
12 Immune Tolerance
13 NHLBI's
14 NIH
15 NIH researcher
16 Neoplasm
17 PD
18 Prevent
19 T cell
20 Tissue Donor
21 Transplant
22 Whole-Body Irradiation
23 accrue
24 acute graft versus host disease
25 administer
26 age
27 allogeneic stem cell transplantation
28 antibiotic
29 appropriate level
30 blood
31 blood sample
32 body
33 bone marrow
34 cancer cell
35 cell
36 cell product
37 chronic leukemia
38 cohort
39 cohort 1
40 cohort 2
41 conditioning regimen
42 cyclophosphamide
43 de-escalation
44 diagnostic category
45 disease relapse
46 dose
47 drug
48 effectiveness
49 efficacy
50 family
51 fludarabine
52 follow-up care
53 follow-up visit
54 grade
55 graft host disease
56 graft-versus-host-disease
57 graft-versus-leukemia
58 graft-versus-leukemia effect
59 healthy tissue
60 hospital
61 host disease
62 immune cell
63 immunity
64 incidence
65 infusion
66 intensity
67 irradiation
68 laboratory procedure
69 laboratory testing
70 life-threatening disease
71 light
72 long-term evaluation
73 low dose
74 lymphocyte
75 machine
76 maximum
77 medicine
78 mortality
79 multiple myeloma
80 myelodysplastic syndrome
81 patient
82 peripheral blood stem cell
83 pharma
84 physician
85 post-transplant
86 primary endpoint
87 protocol
88 rejection
89 residual tumor cell
90 risk
91 rule
92 safety
93 same amount
94 same level
95 same time
96 secondary endpoint
97 selection
98 selective depletion
99 serious complication
100 sibling
101 stage
102 stem cell
103 stem cell transplant
104 stem cell transplantation
105 stop
106 survival
107 syndrome
108 technique
109 tissue
110 toxicity
111 transfusion
112 translational strategy
113 transplant outcome
114 transplantation
115 tube
116 unit
117 vein
118 schema:name Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies
119 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00467961
120 schema:sdDatePublished 2019-03-07T15:22
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N81a2c95eab2543c08a09c9b4c6002d60
123 schema:sponsor https://www.grid.ac/institutes/grid.279885.9
124 https://www.grid.ac/institutes/grid.410305.3
125 schema:startDate 2007-04-01T00:00:00Z
126 schema:subjectOf sg:pub.10.1038/35077251
127 sg:pub.10.1038/bmt.2013.39
128 https://doi.org/10.1016/j.bbmt.2011.05.019
129 https://doi.org/10.1016/s0140-6736(02)09413-8
130 https://doi.org/10.1182/blood-2002-11-3516
131 https://doi.org/10.3324/haematol.2011.053363
132 schema:url https://clinicaltrials.gov/show/NCT00467961
133 sgo:license sg:explorer/license/
134 sgo:sdDataset clinical_trials
135 rdf:type schema:MedicalStudy
136 N81a2c95eab2543c08a09c9b4c6002d60 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
139 rdf:type schema:DefinedTerm
140 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
141 rdf:type schema:DefinedTerm
142 sg:pub.10.1038/35077251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023027862
143 https://doi.org/10.1038/35077251
144 rdf:type schema:CreativeWork
145 sg:pub.10.1038/bmt.2013.39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008987049
146 https://doi.org/10.1038/bmt.2013.39
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1016/j.bbmt.2011.05.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013988099
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/s0140-6736(02)09413-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044804794
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1182/blood-2002-11-3516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036792469
153 rdf:type schema:CreativeWork
154 https://doi.org/10.3324/haematol.2011.053363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032739336
155 rdf:type schema:CreativeWork
156 https://www.grid.ac/institutes/grid.279885.9 schema:Organization
157 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...